Between the years 2000-2010, Penn's Dr.
Howard C. Herrmann was a pioneer in transaortic valve replacement (TAVR), at a time when open-heart surgery was the primary option for patients with valvular disease. In this podcast interview, Dr. Herrmann updates us on investigational research in the field, and describes how TAVR will impact cardiovascular care across the broad therapeutic landscape.